CING Stock Overview
A biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Cingulate Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.32 |
52 Week High | US$21.20 |
52 Week Low | US$0.31 |
Beta | -0.94 |
11 Month Change | -54.29% |
3 Month Change | -70.91% |
1 Year Change | -98.28% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.64% |
Recent News & Updates
Shareholder Returns
CING | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -44.8% | 1.0% | 0.3% |
1Y | -98.3% | 19.1% | 22.5% |
Return vs Industry: CING underperformed the US Pharmaceuticals industry which returned 19.1% over the past year.
Return vs Market: CING underperformed the US Market which returned 22.5% over the past year.
Price Volatility
CING volatility | |
---|---|
CING Average Weekly Movement | 17.2% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CING's share price has been volatile over the past 3 months.
Volatility Over Time: CING's weekly volatility has decreased from 31% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 13 | Shane Schaffer | www.cingulate.com |
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety.
Cingulate Inc. Fundamentals Summary
CING fundamental statistics | |
---|---|
Market cap | US$4.04m |
Earnings (TTM) | -US$22.50m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs CING overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CING income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | -US$321.63k |
Gross Profit | US$321.63k |
Other Expenses | US$22.82m |
Earnings | -US$22.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.26 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CING perform over the long term?
See historical performance and comparison